A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers

Trial Profile

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Sacituzumab govitecan (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Immunomedics
  • Most Recent Events

    • 10 Jul 2017 Results published in the Immunomedics media release.
    • 05 Jul 2017 Results assessing safety and efficacy of Sacituzumab Govitecan in metastatic small-cell lung cancer patients (n=53), published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 26 May 2017 Results assessing safety and efficacy of Sacituzumab Govitecan in heavily-pretreated metastatic non-small-cell lung cancer patients (n=54) published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top